Isavuconazole
From Wikipedia, the free encyclopedia
|
Isavuconazole
|
|
| Systematic (IUPAC) name | |
| 4-[2-[(2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C22H17F2N5OS |
| Mol. mass | 437.47 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Isavuconazole is a triazole antifungal currently in Phase III clinical trials.
|
|||||||||||||||||

